NPCE logo

NPCE
NeuroPace Inc

332
Mkt Cap
$493.22M
Volume
123,176.00
52W High
$18.98
52W Low
$7.56
PE Ratio
-21.61
NPCE Fundamentals
Price
$14.26
Prev Close
$14.65
Open
$14.59
50D MA
$14.39
Beta
1.15
Avg. Volume
260,671.35
EPS (Annual)
-$0.656
P/B
25.16
Rev/Employee
$478,401.91
$515.01
Loading...
Loading...
News
all
press releases
NeuroPace to Present at the 25th Annual Needham Virtual Healthcare Conference
NeuroPace, Inc. (Nasdaq: NPCE), a medical device company focused on transforming the lives of people living with epilepsy, today announced that its management team will present at the 25th Annual...
Business Wire·9h ago
News Placeholder
More News
News Placeholder
NeuroPace (NPCE) Up 0.9% Since Last Earnings Report: Can It Continue?
NeuroPace (NPCE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Zacks·9d ago
News Placeholder
Here's Why You Should Add NeuroPace Stock to Your Portfolio Now
NPCE rides strong RNS adoption and AI innovation, but near-term profitability faces pressure as IGE expansion and revenue contribution remain uncertain.
Zacks·9d ago
News Placeholder
Wall Street Analysts See a 41.29% Upside in NeuroPace (NPCE): Can the Stock Really Move This High?
The average of price targets set by Wall Street analysts indicates a potential upside of 41.3% in NeuroPace (NPCE). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
Zacks·9d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Upgraded at Wells Fargo & Company
Wells Fargo & Company upgraded shares of NeuroPace to a "strong-buy" rating in a research report on Wednesday...
MarketBeat·23d ago
News Placeholder
NeuroPace (NASDAQ:NPCE) Stock Rating Lowered by Wall Street Zen
Wall Street Zen cut NeuroPace from a "buy" rating to a "hold" rating in a research note on Sunday...
MarketBeat·27d ago
News Placeholder
Key Catalysts That Will Likely Drive Prospects for NPCE Stock in 2026
NPCE heads into 2026 with 20%+ RNS growth targets, higher Medicare reimbursement and a cleaner revenue mix as the DIXI distribution business rolls off.
Zacks·1mo ago
News Placeholder
NPCE RNS System Explained: Growth Drivers and Setup for 2026
NPCE enters 2026 with rising RNS adoption, stronger margins and Medicare payment hikes that could boost hospital economics for replacement procedures.
Zacks·1mo ago
News Placeholder
NeuroPace's Seizure ID and New Indication Could Expand RNS Demand
NPCE's Seizure ID AI tool and potential idiopathic generalized epilepsy approval could expand RNS adoption as NeuroPace pushes software-driven care in 2026.
Zacks·1mo ago
News Placeholder
NeuroPace, Inc. (NASDAQ:NPCE) Receives Consensus Rating of "Moderate Buy" from Brokerages
NeuroPace, Inc. (NASDAQ:NPCE - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eight ratings firms that are covering the stock, MarketBeat reports. One research...
MarketBeat·1mo ago
<
1
2
...
>

Latest NPCE News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.